

# Special Issue

## Insights into Urologic Cancer

### Message from the Guest Editors

We are pleased to invite you to submit a manuscript to the Special Issue “Insights into Urological Cancer”. Urological malignancies account for a fifth of newly diagnosed cancers in Western countries. Despite advances in medical tumor therapy, metastatic disease is a common cause of death in patients with a prostate, bladder, or kidney cancer. The development of new therapeutic approaches enables a better understanding of molecular changes in urological tumors. In addition, molecular stratification is necessary to achieve individualized therapies in the future. This Special Issue of *Cancers*, therefore, welcomes original research articles and reviews related to urological malignancies. We look forward to receiving your contributions. Dr. Jörg Ellinger

---

### Guest Editors

Dr. Jörg Ellinger

University Hospital Bonn, Clinic for Urology and Pediatric Urology, Bonn, Germany

Dr. Niklas Klümper

University Hospital Bonn, Clinic for Urology and Pediatric Urology, Bonn, Germany

---

### Deadline for manuscript submissions

closed (31 March 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/97661](https://mdpi.com/si/97661)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)